Dr. Mark Roger Olsen, MD

Dr. Olsen practices at Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma.

Dr. Olsen's NPI, 1356382592, was assigned on June 9, 2006. Dr. Olsen graduated from University of Wisconsin School of Medicine in 1992. Dr. Olsen holds Oklahoma license 20723.

Dr. Olsen's primary practice is Oklahoma Cancer Specialists and Research Institute, at 12697 E 51st S St, Tulsa, OK 74146 in Tulsa County. The practice phone is (918) 505-3200.

Dr. Olsen's primary practice is Oklahoma Cancer Specialists and Research Institute in Tulsa, Oklahoma. Dr. Olsen is also affiliated with Saint Francis Hospital. The medical group on file is Oklahoma Cancer Specialists and Research Institute. Dmand AI also links Dr. Olsen to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Olsen practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Olsen's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Olsen is licensed in Oklahoma.

CMS data shows 166,772 Medicare services from Dr. Olsen across 89 procedure codes in 2024, for 1,068 Medicare patients. Medicare paid $2,333,968 for them. Every service was in an office.

CMS counts 1,068 Medicare patients who saw Dr. Olsen in 2024. The largest group is 65 to 74, with 493 patients. 75% of them have high blood pressure, and 65% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Olsen's median patient age at 71, with 52% women.

In 2024, Dr. Olsen wrote 1,054 Medicare Part D claims for 199 patients. 79% of them were for generic drugs. CMS names the drug for 847 of them, across 29 drugs with 11 or more claims each, at $1,918,843 in total drug cost. In 2023, CMS named 895 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Olsen for performance year 2024, reported individually. Dr. Olsen accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Olsen, published from 2012 to 2021. 2013 was the busiest year, with 2. The most frequent topics are Carcinoma, Renal Cell, Kidney Neoplasms and Nivolumab. Dr. Olsen has published most often in Clin Genitourin Cancer. Dr. Olsen's most frequent co-authors are Philip D. Bonomi, MD, Edward R. Arrowsmith, MD and Edward Brian Garon, MD.

Dmand AI links Dr. Olsen to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Sarcoma and Neoplasms, Connective and Soft Tissue. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Olsen that name 1 trial.

CMS Open Payments shows 153 general payments to Dr. Olsen from 44 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Daiichi Sankyo Inc. paid the most, $426. It also lists 3 research payments totaling $1,844 from 2017 to 2018, naming 1 clinical trial.

Dr. Olsen graduated from University of Wisconsin School of Medicine in 1992.